Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has announced an upcoming webinar featuring CEO Dr. Chris Burns, who will introduce the company and its focus on developing FAK inhibitors for treating cancer and fibrosis. The presentation will include a live Q&A session and is part of a series by Sharewise, accessible online to shareholders and interested parties. Amplia is targeting diseases like pancreatic cancer and idiopathic pulmonary fibrosis with their research into FAK, a promising area in cancer treatment.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
